The Utility of Thrombus Aspiration for NSTEMI Déjà Vu of Aspiration for Primary PCI∗ by Waksman, Ron & Lipinski, Michael J.
J O U R N A L O F T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y V O L . 6 4 , N O . 1 1 , 2 0 1 4
ª 2 0 1 4 B Y T H E A M E R I C A N CO L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 4 . 0 6 . 1 1 7 6EDITORIAL COMMENTThe Utility of Thrombus Aspiration
for NSTEMI
Déjà Vu of Aspiration for Primary PCI*Ron Waksman, MD, Michael J. Lipinski, MD, PHDSEE PAGE 1117T he presence of heavy thrombus burden at thetime of percutaneous coronary intervention(PCI) for acute myocardial infarction (AMI)
is associated with an increased incidence of major
adverse cardiovascular events (MACE) during
follow-up (1). Distal embolization of thrombus can
lodge in the smaller arterioles and capillaries down-
stream, leading to suboptimal angiographic results
after PCI with reduced Thrombolysis In Myocardial
Infarction (TIMI) ﬂow and myocardial blush grade
(2). The resulting microvascular obstruction (MO) pre-
vents gadolinium from entering the downstream
region of myocardium and is characterized by an
area of signal void within the surrounding bright
infarct on late gadolinium-enhancement cardiac mag-
netic resonance (CMR) T1 imaging. The hope has been
that thrombus aspiration will prevent distal emboli-
zation and result in signiﬁcant improvement of
outcomes after PCI for AMI. However, the recent
large TASTE (Thrombus Aspiration in Myocardial
Infarction) trial involving 7,244 patients did not
demonstrate a beneﬁt for death (3). Meanwhile, a
meta-analysis of randomized, controlled trials, in-
cluding TASTE, suggests that aspiration thrombec-
tomy compared with conventional primary PCI
resulted in a signiﬁcant reduction in reinfarction,
stent thrombosis, and late mortality (4). Although*Editorials published in the Journal of the American College of Cardiology
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STEMI than in patients with non-STEMI (NSTEMI)
(5), the question remains whether patients with
thrombus present on angiography for NSTEMI will
beneﬁt from routine thrombus aspiration or should
thrombus aspiration be used only in certain cases
based on the clinical scenario. In the case of NSTEMI,
aspiration devices are less commonly used, as seen
in the ACUITY (Acute Catheterization and Urgent
Intervention Triage Strategy) trial, in which thrombus
aspiration was used in only 2% of patients (6). Will
the utility of thrombus aspiration for NSTEMI be
a primary PCI déjà vu?In this issue of the Journal, Thiele et al. (7) present
the ﬁndings of the TATORT-NSTEMI (Thrombus
Aspiration in Thrombus Containing Culprit Lesions in
Non-ST-Elevation Myocardial Infarction) trial in
which the authors randomized 440 patients with
angiographic evidence of a thrombus-containing
lesion at the time of PCI to either adjuvant aspira-
tion thrombectomy and PCI or PCI alone. Interest-
ingly, the authors selected the extent of late MO in the
percentage of left ventricular mass on CMR imaging
performed 1 to 4 days after PCI as the primary
endpoint for the study, with other CMR and angio-
graphic parameters as well as clinical outcomes as the
secondary study endpoints. The study found that
adjuvant thrombus aspiration at the time of PCI did
not signiﬁcantly reduce the amount of late MO, reduce
infarct size, or improve TIMI ﬂow grade, myocardial
blush, or other CMR or angiographic outcomes (7).
Furthermore, clinical outcomes of death, reinfarction,
target vessel revascularization, or new congestive
heart failure were not signiﬁcantly different at
6-month follow-up, although the study was not
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Given that the study enrolled 20 fewer patients than
expected and the MO size by left ventricular mass in
this study was quite small (1.7%), with an MO
prevalence of 31%, the question is raised whether
the primary outcome was properly powered as
these values are lower than those predicted of 2%
and 40%, respectively, in the initial trial design (8).
This study raises several questions as to why MO
was not signiﬁcantly decreased with aspiration
thrombectomy. 1) Is MO the best surrogate endpoint
to select, or should hard endpoints have been used?
2) Does time to PCI affect MO and outcomes?
3) Does the lack of beneﬁt of aspiration thrombec-
tomy simply reﬂect smaller thrombus burden with
NSTEMI compared with STEMI?
With regard to the ﬁrst question, the choice of
MO on CMR imaging may not be the best choice to
reﬂect hard endpoints after PCI. Although several
studies previously suggested that late MO was asso-
ciated with poor prognosis after AMI (9), a recent
systematic review and meta-analysis assessing the
prognostic value of multiple CMR predictors of prog-
nosis demonstrated that there is not enough evidence
to support the use of MO for prognostication in pa-
tients with recent MI (10). With regard to the second
question, the time to aspiration thrombectomy may
play an important role. A recent meta-regression
analysis of randomized controlled trials comparing
adjuvant aspiration thrombectomy with conventional
PCI suggested greater beneﬁt for mortality with
aspiration thrombectomy compared with conven-
tional PCI with longer time from symptom onset to
treatment (11). This concurs with results of De Vita
et al. (12), who found decreasing beneﬁt with con-
ventional PCI over time but no such decrease for
aspiration thrombectomy and PCI in the treatment of
AMI. These data imply that perhaps the longer the
thrombus has time to organize, the less effective
aspiration thrombectomy can be, suggesting such
extraction techniques would be less effective in the
NSTEMI compared with a fresh thrombus in STEMI. In
addition, the increased time to PCI with NSTEMI also
may result in a greater incidence of distal emboliza-
tion before PCI, abrogating the effectiveness of aspi-
ration thrombectomy. Finally, thrombus burden in
NSTEMI is often less than in STEMI, raising the
question whether the decreased incidence and
burden of thrombus with NSTEMI are inadequate to
derive a signiﬁcant beneﬁt like that suggested in
STEMI. The issue of direct stenting also was different
between the groups but did not appear to affect
MO. In the TATORT-NSTEMI trial, neither the degree
of thrombus burden nor the use of direct stentingappeared to affect MO, whereas variables associated
with MO were pre-PCI TIMI ﬂow, diabetes mellitus,
and culprit lesion in the left anterior descending or
left circumﬂex artery (7). Thus, aspiration throm-
bectomy appears largely negative in all groups of
NSTEMI patients and implies that, although not
harmful, aspiration thrombectomy does not beneﬁt
those even with large thrombus burden.
Because of the cost of designing large multicenter,
randomized, controlled trials, the use of surrogate
endpoints rather than the hard endpoints of death
and reinfarction is likely to continue. However, we
have to be conﬁdent in the surrogate endpoint, so if
the study results are negative, one must be willing to
accept that the question has been sufﬁciently
addressed. In the case of TATORT-NSTEMI trial,
although late MO is not signiﬁcantly reduced with
thrombus aspiration, we are not certain that the same
can be said for MACE. It is important to note that the
upcoming TAPAS II (Thrombus Aspiration During
Percutaneous Coronary Intervention in Acute Non-
ST-Elevation Myocardial Infarction Study) has
selected myocardial blush grade as the primary
endpoint and also will likely be underpowered to
assess clinical endpoints of death, reinfarction, or
MACE (13). On the other hand, it may be impossible to
examine this question in a clinical trial because
aspiration thrombectomy will likely continue to be
used in certain patients based on the variability of
other confounders, such as thrombus size, thrombus
age, and infarct size. Without any deﬁnitive data to
support routine thrombus aspiration for all patients
and all lesions, as with the STEMI indication, we
should continue to perform procedures that we
believe are in the best interest of our patients. Phy-
sicians may use it primarily in patients with large
thrombus burden and with TIMI ﬂow grade 0 to
enable accurate stent placement. Before closing the
door on aspiration thrombectomy, let’s wait for the
upcoming results from the TOTAL (A Trial of Routine
Aspiration Thrombectomy With Percutaneous Coro-
nary Intervention [PCI] Versus PCI Alone in Patients
With ST-Segment Elevation Myocardial Infarction
[STEMI] Undergoing Primary PCI), which will recruit
>10,000 patients and should help provide a deﬁnitive
answer as to whether aspiration thrombectomy pro-
vides clinical beneﬁt in patients with AMI (14). Could,
however, the utility of aspiration thrombectomy in
NSTEMI be déjà vu?
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